{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:09:43Z","timestamp":1783008583154,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Denosumab is a major treatment option for patients with postmenopausal osteoporosis; however, the evidence for its use is lacking. Therefore, in this 24-month retrospective study, we aimed to evaluate the effects of switching from minodronate (MIN) to denosumab in these patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients with postmenopausal osteoporosis either switched from MIN to denosumab (Group 1; <jats:italic>n<\/jats:italic>\u2009=\u200932) or continued MIN treatment (Group 2; <jats:italic>n<\/jats:italic>\u2009=\u200924). Bone mineral density (BMD) of the lumbar spine (L2\u2013L4) and femoral neck was assessed at baseline and every 6\u2009months for 24\u2009months. Serum bone-specific alkaline phosphatase (BAP) and N-terminal telopeptide were measured at baseline, 12\u2009months, and 24\u2009months.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Twenty-nine of the 32 patients (90.6%) in group 1 and all patients (24\/24) in group 2 completed the 24-month follow-up. Switching from MIN to denosumab (Group 1) significantly increased lumbar BMD at 12, 18, and 24\u2009months (6.1, 7.4, and 9.6%, respectively) and femoral neck BMD at 12, 18, and 24\u2009months (2.8, 3.2, and 3.4%, respectively), whereas MIN continuous treatment (Group 2) showed no significant difference from baseline. Switching therapy also showed a significant decrease in serum BAP from baseline to 12 and 24\u2009months (\u2212\u200919.3 and\u2009\u2212\u200926.5%, respectively) and serum NTX from baseline to 12\u2009months (\u2212\u200913.1%), whereas continuous MIN treatment failed to show any significant differences from baseline.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Switching from MIN to denosumab in patients with postmenopausal osteoporosis showed clinical benefits with regard to BMD and bone turnover markers in comparison with continuous MIN treatment. It may therefore be a valid treatment option in the clinical setting.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12905-020-00913-x","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T10:03:31Z","timestamp":1583402611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study"],"prefix":"10.1186","volume":"20","author":[{"given":"Masaki","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasa","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoso","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"913_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3389\/fphar.2017.00803","volume":"8","author":"V Pavone","year":"2017","unstructured":"Pavone V, Testa G, Giardina SMC, Vescio A, Restivo DA, Sessa G. Pharmacological therapy of osteoporosis: a systematic current review of literature. Front Pharmacol. 2017;8:803.","journal-title":"Front Pharmacol"},{"key":"913_CR2","first-page":"435","volume":"7","author":"S Das","year":"2013","unstructured":"Das S, Crockett JC. Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 2013;7:435\u201348.","journal-title":"Drug Des Devel Ther"},{"key":"913_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nrendo.2015.71","volume":"11","author":"IR Reid","year":"2015","unstructured":"Reid IR. Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol. 2015;11:418\u201328.","journal-title":"Nat Rev Endocrinol"},{"key":"913_CR4","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2106\/JBJS.J.01539","volume":"94","author":"G Holt","year":"2012","unstructured":"Holt G, Smith R, Duncan K, Hutchison JD, Gregori A, Reid D. Outcome after sequential hip fracture in the elderly. J Bone Joint Surg Am. 2012;94:1801\u20138.","journal-title":"J Bone Joint Surg Am"},{"key":"913_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1467-842X.1996.tb01069.x","volume":"20","author":"RG Cumming","year":"1996","unstructured":"Cumming RG, Klineberg R, Katelaris A. Cohort study of risk of institutionalisation after hip fracture. Aust N Z J Public Health. 1996;20:579\u201382.","journal-title":"Aust N Z J Public Health"},{"key":"913_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1136\/bmj.307.6914.1248","volume":"307","author":"GS Keene","year":"1993","unstructured":"Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. BMJ. 1993;307:1248\u201350.","journal-title":"BMJ."},{"key":"913_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4:46\u201356.","journal-title":"Eur J Rheumatol"},{"key":"913_CR8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.mcna.2014.03.007","volume":"98","author":"MA Varacallo","year":"2014","unstructured":"Varacallo MA, Fox EJ. Osteoporosis and its complications. Med Clin North Am. 2014;98:817\u201331.","journal-title":"Med Clin North Am"},{"key":"913_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.maturitas.2018.11.010","volume":"120","author":"P Anagnostis","year":"2019","unstructured":"Anagnostis P, Gkekas NK, Potoupnis M, Kenanidis E, Tsiridis E, Goulis DG. New therapeutic targets for osteoporosis. Maturitas. 2019;120:1\u20136.","journal-title":"Maturitas"},{"key":"913_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2147\/CIA.S23927","volume":"8","author":"S Tanishima","year":"2013","unstructured":"Tanishima S, Morio Y. A review of minodronic acid hydrate for the treatment of osteoporosis. Clin Interv Aging. 2013;8:185\u20139.","journal-title":"Clin Interv Aging"},{"key":"913_CR11","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00198-008-0816-7","volume":"20","author":"T Matsumoto","year":"2009","unstructured":"Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int. 2009;20:1429\u201337.","journal-title":"Osteoporos Int"},{"key":"913_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/PPA.S46192","volume":"8","author":"T Miyazaki","year":"2014","unstructured":"Miyazaki T, Tokimura F, Tanaka S. A review of denosumab for the treatment of osteoporosis. Patient Prefer Adherence. 2014;8:463\u201371.","journal-title":"Patient Prefer Adherence"},{"key":"913_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756\u201365.","journal-title":"N Engl J Med"},{"key":"913_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513\u201323.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"913_CR15","volume-title":"Personal pages of answers News","author":"A News","year":"2019","unstructured":"Answers News. Personal pages of answers News. 2019. https:\/\/answers.ten-navi.com\/pharmanews\/15774\/. Accessed 20 Mar 2019."},{"key":"913_CR16","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1210\/jc.2018-02236","volume":"104","author":"H Lyu","year":"2019","unstructured":"Lyu H, Jundi B, Xu C, Tedeschi SK, Yoshida K, Zhao S, et al. Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2019;104:1753\u201365.","journal-title":"J Clin Endocrinol Metab"},{"key":"913_CR17","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99:2599\u2013607.","journal-title":"J Clin Endocrinol Metab"},{"key":"913_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, et al. Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab. 2013;31:247\u201357.","journal-title":"J Bone Miner Metab"},{"key":"913_CR19","first-page":"730","volume":"79","author":"A Blumsohn","year":"1994","unstructured":"Blumsohn A, Herrington K, Hannon RA, Shao P, Eyre DR, Eastell R. The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab. 1994;79:730\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"913_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677\u201392.","journal-title":"Bone."},{"key":"913_CR21","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016;101:3163\u201370.","journal-title":"J Clin Endocrinol Metab"},{"key":"913_CR22","first-page":"444","volume":"17","author":"A Augoulea","year":"2017","unstructured":"Augoulea A, Tsakonas E, Triantafyllopoulos I, Rizos D, Armeni E, Tsoltos N, et al. Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women. J Musculoskelet Neuronal Interact. 2017;17:444\u20139.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"913_CR23","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012;66:1139\u201346.","journal-title":"Int J Clin Pract"},{"key":"913_CR24","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1097\/GME.0000000000000696","volume":"23","author":"RL Drieling","year":"2016","unstructured":"Drieling RL, LaCroix AZ, Beresford SAA, Boudreau DM, Kooperberg C, Chlebowski RT, et al. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative. Menopause. 2016;23:1168\u201375.","journal-title":"Menopause."},{"key":"913_CR25","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1111\/jgs.14911","volume":"65","author":"RL Drieling","year":"2017","unstructured":"Drieling RL, LaCroix AZ, Beresford SAA, Boudreau DM, Kooperberg C, Chlebowski RT, et al. Long-term oral bisphosphonate therapy and fractures in older women: the women's health initiative. J Am Geriatr Soc. 2017;65:1924\u201331.","journal-title":"J Am Geriatr Soc"},{"key":"913_CR26","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","volume":"26","author":"L Karlsson","year":"2015","unstructured":"Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Str\u00f6m O. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015;26:2401\u201311.","journal-title":"Osteoporos Int"},{"key":"913_CR27","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","volume":"121","author":"C Recknor","year":"2013","unstructured":"Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121:1291\u20139.","journal-title":"Obstet Gynecol"},{"key":"913_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014;58:48\u201354.","journal-title":"Bone"},{"key":"913_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou C, Brown J, Lillestol M, Siddhanti S, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72\u201381.","journal-title":"J Bone Miner Res"},{"key":"913_CR30","first-page":"9","volume":"15","author":"Y Chatani","year":"2005","unstructured":"Chatani Y. Minodronic acid hydrate as a new therapeutic agent for osteoporosis. Clin Calcium. 2005;15:9\u201314.","journal-title":"Clin Calcium"},{"key":"913_CR31","first-page":"235","volume":"296","author":"JE Dunford","year":"2001","unstructured":"Dunford JE, Thmpson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235\u201342.","journal-title":"J Pharmacol Exp Ther"},{"key":"913_CR32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2147\/TCRM.S149236","volume":"14","author":"T Ohishi","year":"2018","unstructured":"Ohishi T, Matsuyama Y. Minodronate for the treatment of osteoporosis. Ther Clin Risk Manag. 2018;14:729\u201339.","journal-title":"Ther Clin Risk Manag"},{"key":"913_CR33","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3949\/ccjm.85a.17119","volume":"85","author":"S Silverman","year":"2018","unstructured":"Silverman S, Kupperman E, Bukata S. Bisphosphonate-related atypical femoral fracture: managing a rare but serious complication. Cleve Clin J Med. 2018;85:885\u201393.","journal-title":"Cleve Clin J Med"},{"key":"913_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.job.2019.03.005","volume":"61","author":"S Kuroshima","year":"2019","unstructured":"Kuroshima S, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: a literature review. J Oral Biosci. 2019;61:99\u2013104.","journal-title":"J Oral Biosci"},{"issue":"1","key":"913_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00198-019-05233-x","volume":"31","author":"P.D. Miller","year":"2019","unstructured":"Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwi\u0144ski E, Bone HG, et al. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int. 2020;31:181\u201391.","journal-title":"Osteoporosis International"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-00913-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12905-020-00913-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-00913-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:11:18Z","timestamp":1614903078000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-020-00913-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1186\/s12905-020-00913-x","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"11 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was approved by the institutional review board of Academic Clinical Research Center of Osaka University (No. 19130) and the procedures followed were in accordance with institutional guidelines. The information about this study was posted on the hospital homepage with waiver of informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have read and approved the content of the article. The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}